GSK, Alector enter into $2.2bn immuno-neurology collaboration
GSK and Alector will develop AL001 and AL101 for the treatment of dementia, sclerosis, Parkinson’s disease and Alzheimer’s…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Jul 21
GSK and Alector will develop AL001 and AL101 for the treatment of dementia, sclerosis, Parkinson’s disease and Alzheimer’s…
05 Jul 21
The data included new analysis from blood samples obtained from a subset of participants in the Phase 3…
01 Jul 21
Rylaze is indicated for ALL/LBL in paediatric and adult patients, who have developed hypersensitivity to E. coli-derived asparaginase
30 Jun 21
The investment will expand FDB’s capacity for recombinant vaccines and advanced gene therapies in the US and the…
30 Jun 21
Moderna’s Covid-19 vaccine is authorised in more than 50 countries and received Emergency Use Listing (EUL) from the…
29 Jun 21
The approval is based on results from Phase 3 SAkuraStar and SAkuraSky clinical trials of Enspryng in people…
28 Jun 21
The settlement facilitates the exclusion of J&J from a trial that is scheduled to start in Suffolk County…
25 Jun 21
The FDA authorisation allows emergency use of Actemra for the treatment of Covid-19 in hospitalised adult and paediatric…
25 Jun 21
Donanemab is an investigational antibody therapy that has shown positive results in treating Alzheimer's disease in clinical trials
24 Jun 21
The NMPA approval was based on positive results from a single-arm Phase 2 trial conducted in NSCLC patients…